Ttoxicity analyses and therapeutic modification of the anti-cancer drug camptothecin

抗癌药物喜树碱的毒性分析和治疗修改

基本信息

项目摘要

Colorectal cancer (CRC) is he second most diagnosed cancer in Germany leading to death of 30000 people per year. Generally, development of CRC is the outcome of interactions between environmental factors and genetic predisposition. The cellular defence system plays an essential role in the detoxification of potentially carcinogenic xenobiotics and consequently in cancer prevention. UDP-glucuronosyltransferases (UGT), as a part of the cellular defence mechanisms, catalyze the detoxification of xenobiotic substances like carcinogens and drugs.Irinotecan is used, depending on the clinical context, in a monotherapy or in combination with other cytostatic agents (FOLFIRI) for the treatment of metastatic CRC. 20-30% of the treated patients suffer from serious side effects like diarrhoea and leucopenia (up to WHO grade 4) representing the dosis limiting toxicity which affects the therapeutic and curative potential of irinotecan. Ubiquitous expressed carboxylesterases catalyze the conversion of irinotecan to its activated but also more toxic metabolite SN38. Glucuronidation by UGTs leads to inactivation and elimination of SN38 via bile and urine. In several studies, a promoter mutation in the UGT1A1 gene (UGT1A1*28) was associated with increased occurrence of serious side effects during irinotecan therapy. However, approximately 50% of the patients carrying this genotype suffered from serious side effects indicating that further factors may play a role in the prediction of diarrhoea and leucopenia. Genotyping of 105 irinotecan treated patients revealed that only the combination of 3 different polymorphisms in the UGT1A7 gene (UGT1A7*3) together with the UGT1A1*28 variant is a reliable predictor for the occurrence of irinotecan-toxocity. Against this background we want to investigate if the SNP-mediated reduced glucuronidation activity can be compensated by appropriate, non-toxic UGT1A-inducers and potentially leads to reduction of irinotecan associated toxicity. Within this project, the effects of the UGT1A-activator coffee on the occurrence and the severity of side effects during irinotecan-treatment should be analyzed. Therefore, a humanized transgenic mouse line is used which carries the above mentioned UGT1A-haplotype as a transgene. The results are compared to those of a second mouse line which carries the human UGT1A gene locus in the wild type form. Additionally, gender specific differences during a coffee attended irinotecan-therapy should be analyzed potentially offering fundamentals for not yet established gender specific therapeutic strategies.
结直肠癌(CRC)是德国第二大诊断癌症,每年导致3万人死亡。一般来说,结直肠癌的发生是环境因素和遗传易感性相互作用的结果。细胞防御系统在潜在致癌物质的解毒和癌症预防中起着至关重要的作用。UDP-glucuronosyltransferases (UGT)作为细胞防御机制的一部分,催化对致癌物和药物等外源物质的解毒。依临床情况而定,伊立替康可用于单药治疗或与其他细胞抑制剂(FOLFIRI)联合治疗转移性结直肠癌。20-30%的治疗患者出现严重副作用,如腹泻和白细胞减少(高达世卫组织第4级),属于剂量限制性毒性,影响伊立替康的治疗和治愈潜力。普遍表达的羧酸酯酶催化伊立替康转化为其活化但毒性更大的代谢物SN38。ugt的糖醛酸化作用导致SN38失活并通过胆汁和尿液消除。在一些研究中,UGT1A1基因(UGT1A1*28)的启动子突变与伊立替康治疗期间严重副作用的发生率增加有关。然而,携带该基因型的患者中约有50%患有严重的副作用,这表明进一步的因素可能在预测腹泻和白细胞减少方面发挥作用。105例伊立替康治疗患者的基因分型显示,UGT1A7基因(UGT1A7*3)的3种不同多态性与UGT1A1*28变异的组合是伊立替康毒性发生的可靠预测因子。在此背景下,我们想研究snp介导的葡萄糖醛酸化活性降低是否可以通过适当的、无毒的ugt1a诱导剂来补偿,并可能导致伊立替康相关毒性的降低。在这个项目中,需要分析ugt1a -活化剂咖啡对伊立替康治疗期间副作用的发生和严重程度的影响。因此,采用一种人源化转基因小鼠系,将上述ugt1a单倍型作为转基因基因携带。结果与第二种携带野生型人类UGT1A基因位点的小鼠系进行了比较。此外,应该分析在伊立替康治疗期间的性别差异,为尚未建立的性别特异性治疗策略提供潜在的基础。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professor Dr. Christian Strassburg其他文献

Professor Dr. Christian Strassburg的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Professor Dr. Christian Strassburg', 18)}}的其他基金

Analysis and modification of the metabolic antioxidative balance as risk factor for liver fibrosis in humanized, transgenic UGT1A SNP and wild type mice
人源化转基因 UGT1A SNP 和野生型小鼠中代谢抗氧化平衡作为肝纤维化危险因素的分析和修改
  • 批准号:
    268209133
  • 财政年份:
    2015
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Charakterisierung der Rolle von Metabolisierungsenzym- und Transporter-Polymorphismen beim hepatozellulären Karzinom (HCC)
代谢酶和转运蛋白多态性在肝细胞癌 (HCC) 中作用的表征
  • 批准号:
    5415098
  • 财政年份:
    2004
  • 资助金额:
    --
  • 项目类别:
    Clinical Research Units
Experimentelle Gastroenterologie
实验胃肠病学
  • 批准号:
    5320322
  • 财政年份:
    2001
  • 资助金额:
    --
  • 项目类别:
    Heisenberg Fellowships
Zytoprotektive und metabolische Rolle der UDP-Glukuronosyltransferasen (UGT) in der Karzinogenese gastrointestinaler Tumoren
UDP-葡萄糖醛酸基转移酶(UGT)在胃肠道肿瘤发生过程中的细胞保护和代谢作用
  • 批准号:
    5134514
  • 财政年份:
    1998
  • 资助金额:
    --
  • 项目类别:
    Research Grants

相似国自然基金

大鱼际掌纹特应征与5个哮喘易感基因单核苷酸多态性的关联分析
  • 批准号:
    30873315
  • 批准年份:
    2008
  • 资助金额:
    31.0 万元
  • 项目类别:
    面上项目

相似海外基金

The role of nigrostriatal and striatal cell subtype signaling in behavioral impairments related to schizophrenia
黑质纹状体和纹状体细胞亚型信号传导在精神分裂症相关行为障碍中的作用
  • 批准号:
    10751224
  • 财政年份:
    2024
  • 资助金额:
    --
  • 项目类别:
Individualized treatment for patients with parapneumonic pleural effusion via therapeutic drug monitoring and metagenomic analyses
通过治疗药物监测和宏基因组分析对肺炎旁胸腔积液患者进行个体化治疗
  • 批准号:
    518875532
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
    Research Grants
Experiences of Discrimination, Dysbiosis, and Racial Disparities in Ovarian Cancer
卵巢癌中的歧视、生态失调和种族差异的经历
  • 批准号:
    10371537
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Mechanistic and Bioinformatics Core
机制和生物信息学核心
  • 批准号:
    10642595
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Investigating Enlarged Perivascular Spaces as a Neuroimaging Biomarker of Cerebral Small Vessel Disease
研究扩大的血管周围空间作为脑小血管疾病的神经影像生物标志物
  • 批准号:
    10674098
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Defining the shared transcriptional network underlying Toxoplasma extracellular stress and stage transition
定义弓形虫细胞外应激和阶段转变背后的共享转录网络
  • 批准号:
    10682134
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Evaluating the Effects of Animal Therapy on Anxiety in Pediatric Dental Patients
评估动物疗法对小儿牙科患者焦虑的影响
  • 批准号:
    10649010
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Neuromodulation for impulsivity and suicidality in Veterans with mildtraumatic brain injury and common co-occurring mental health conditions
神经调节对患有轻度脑损伤和常见并发心理健康状况的退伍军人的冲动和自杀倾向
  • 批准号:
    10640567
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Arginase-1 signaling after neonatal stroke
新生儿中风后精氨酸酶 1 信号转导
  • 批准号:
    10664501
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Biomarker Discovery in Portopulmonary Hypertension
门脉性肺动脉高压的生物标志物发现
  • 批准号:
    10663708
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了